Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873367 | 1.00 | MAOB (0.48) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL483622 | 1.00 | MAOB (0.48) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL483470 | 0.87 | MAOB (0.51) | MAOBNR4A2SMN1; SMN2SRD5A2FFAR4 | |
| SCHEMBL310304 | 0.86 | MAOB (0.52) | MAOBPARP10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL483664 | 0.84 | MAOB (0.47) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL310921 | 0.72 | CA1 (0.50) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL483619 | 0.72 | CA1 (0.50) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL17873425 | 0.72 | CA1 (0.50) | MAOBCA1CA2NR4A2NR4A1 | |
| SCHEMBL12079897 | 0.72 | MAOB (0.50) | MAOBPARP10NPC1RAB9ASMN1; SMN2 | |
| Bicarbonate SCHEMBL9638235 | 0.71 | FFAR1 (0.71) | MAOBNR4A2NR4A1NR4A3GSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237379-B1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CONVERGENCE PHARMACEUTICALS (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-10421716-B2 | Process for preparing alpha-carboxamide pyrrolidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | Convergence Pharmaceuticals Limited (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-3237379-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102967-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2016-06-30 | — | — | WO | disclosed |
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-1934176-B1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-8093268-B2 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | MAOB 1571/4885CA1 733/4885CA2 244/4885 |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | KCNJ2, TRPV1, SCN5A | MAOB 1017/4885CA1 1620/4885CA2 350/4885 |
| US-10421716-B2 | Process for preparing alpha-carboxamide pyrrolidine derivatives | CPS1, ALDH18A1, PCCA | MAOB 78/4885CA1 1685/4885CA2 1855/4885 |
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | CPS1, ALDH18A1, PCCA | MAOB 78/4885CA1 1685/4885CA2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.